NASDAQ:HSIC - Henry Schein Stock Price, Price Target & More

Henry Schein trades on the NASDAQ under the ticker symbol "HSIC."

Shares of Henry Schein split before market open on Friday, September 15th 2017. The 2-1 split was announced on Wednesday, August 16th 2017. The newly created shares were payable to shareholders after the market closes on Thursday, September 14th 2017. An investor that had 100 shares of Henry Schein stock prior to the split would have 200 shares after the split.

Henry Schein declared that its Board of Directors has initiated a stock buyback program on Tuesday, September 19th 2017, which permits the company to buyback $400,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to buy up to 6.3% of its stock through open market purchases. Stock buyback programs are typically an indication that the company's board believes its shares are undervalued.

Henry Schein, Inc. (NASDAQ:HSIC) announced its earnings results on Tuesday, May, 8th. The company reported $0.95 earnings per share for the quarter, beating analysts' consensus estimates of $0.92 by $0.03. The company earned $3.22 billion during the quarter, compared to analysts' expectations of $3.18 billion. Henry Schein had a return on equity of 19.68% and a net margin of 3.18%. Henry Schein's revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.88 EPS. View Henry Schein's Earnings History.

Henry Schein updated its FY18 earnings guidance on Tuesday, May, 8th. The company provided earnings per share (EPS) guidance of $4.03-4.14 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.09.

19 brokerages have issued 12-month price targets for Henry Schein's stock. Their forecasts range from $73.00 to $102.00. On average, they anticipate Henry Schein's share price to reach $81.50 in the next twelve months. View Analyst Ratings for Henry Schein.

Henry Schein saw a increase in short interest in the month of May. As of May 31st, there was short interest totalling 20,773,220 shares, an increase of 12.3% from the May 15th total of 18,492,187 shares. Based on an average trading volume of 1,381,966 shares, the days-to-cover ratio is presently 15.0 days. Currently, 13.7% of the company's stock are sold short. View Henry Schein's Current Options Chain.

Some companies that are related to Henry Schein include Boston Scientific (BSX), Zoetis (ZTS), Illumina (ILMN), Humana (HUM), BEXIMCO PHARMAC/S GDR REGS (BXP), Vertex Pharmaceuticals (VRTX), Baxter International (BAX), HCA Healthcare (HCA), Regeneron Pharmaceuticals (REGN), Edwards Lifesciences (EW), Takeda Pharmaceutical (TKPYY), ASTELLAS PHARMA/ADR (ALPMY), Fresenius Medical Care AG & Co. (FMS), ESSILOR Intl S/S (ESLOY) and Actelion (ALIOF).

Media stories about HSIC stock have been trending somewhat positive recently, Accern reports. The research group identifies negative and positive press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Henry Schein earned a news impact score of 0.22 on Accern's scale. They also gave headlines about the company an impact score of 47.45 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

Henry Schein's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.50%), Select Equity Group L.P. (4.20%), Alecta Pensionsforsakring Omsesidigt (3.57%), JPMorgan Chase & Co. (1.66%), Atlanta Capital Management Co. L L C (1.61%) and Swedbank (1.41%). Company insiders that own Henry Schein stock include Barry J Alperin, Donald J Kabat, Gerald A Benjamin, James A Harding, Kurt P Kuehn, Lorelei Mcglynn, Mark E Mlotek, Michael Racioppi, Michael S Ettinger, Paul Brons, Paul Rose, Philip A Laskawy and Steven Paladino. View Institutional Ownership Trends for Henry Schein.

HSIC stock was sold by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Green Valley Investors LLC, BlackRock Inc., Virginia Retirement Systems ET AL, Glen Harbor Capital Management LLC, Neuberger Berman Group LLC, Russell Investments Group Ltd. and Swedbank. Company insiders that have sold Henry Schein company stock in the last year include Barry J Alperin, Mark E Mlotek, Paul Brons and Paul Rose. View Insider Buying and Selling for Henry Schein.

HSIC stock was bought by a variety of institutional investors in the last quarter, including Select Equity Group L.P., American Century Companies Inc., Kovitz Investment Group Partners LLC, Wells Fargo & Company MN, Alecta Pensionsforsakring Omsesidigt, New York State Common Retirement Fund, Polar Asset Management Partners Inc. and The Manufacturers Life Insurance Company. View Insider Buying and Selling for Henry Schein.

Shares of HSIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of HSIC stock can currently be purchased for approximately $74.69.

Henry Schein has a market capitalization of $11.10 billion and generates $12.46 billion in revenue each year. The company earns $406.29 million in net income (profit) each year or $3.60 on an earnings per share basis. Henry Schein employs 22,000 workers across the globe.

Henry Schein's mailing address is 135 DURYEA RD, MELVILLE NY, 11747. The company can be reached via phone at 631-843-5500 or via email at [email protected]